These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17208382)

  • 21. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
    Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S
    Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
    Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
    Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine.
    Bender S; Dittmann-Balcar A; Schall U; Wolstein J; Klimke A; Riedel M; Vorbach EU; Kühn KU; Lambert M; Dittmann RW; Naber D
    Int J Neuropsychopharmacol; 2006 Apr; 9(2):135-45. PubMed ID: 16174427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
    Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
    de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD
    Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients.
    Strous RD; Maayan R; Kotler M; Weizman A
    Clin Neuropharmacol; 2005; 28(6):265-9. PubMed ID: 16340380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.
    Strous RD; Maayan R; Lapidus R; Goredetsky L; Zeldich E; Kotler M; Weizman A
    Schizophr Res; 2004 Dec; 71(2-3):427-34. PubMed ID: 15474914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
    Hofer A; Rettenbacher MA; Edlinger M; Huber R; Bodner T; Kemmler G; Sachs G; Fleischhacker WW
    Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
    Shaw P; Sporn A; Gogtay N; Overman GP; Greenstein D; Gochman P; Tossell JW; Lenane M; Rapoport JL
    Arch Gen Psychiatry; 2006 Jul; 63(7):721-30. PubMed ID: 16818861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.